BIOGEN INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218.4 USD | -3.03% |
|
-4.57% | -15.17% |
| 05-22 | US Equity Markets Close Down Wednesday After Fed Minutes Raise Inflation Concerns | MT |
| 05-22 | Sector Update: Health Care Stocks Slightly Higher Late Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
20/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
225.2
USD
Average target price
287.3
USD
Spread / Average Target
+27.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.17% | 32.79B | |
| -1.62% | 89.22B | |
| +2.24% | 40.49B | |
| +63.18% | 26.23B | |
| -21.54% | 14.52B | |
| -7.57% | 13.09B | |
| -42.60% | 11.6B | |
| -12.64% | 11.5B | |
| +5.32% | 8.82B | |
| -13.45% | 7.92B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen : Eisai Get FDA's Breakthrough Therapy Designation for Alzheimer's Disease Treatment
